Milon Biswas

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

1. Introduction Brain atrophy is a clinically relevant biomarker of disease progression in patients with multiple sclerosis (MS) that reflects irreversible tissue damage due to neuro-axonal destruction, demyelination and gliosis (Bermel and Bakshi, 2006). Accelerated brain tissue loss can be detected in MS cohorts compared to a healthy control population (De Stefano et al., 2016).